American Addiction Centers Names Desert Hope Treatment Center a Veterans Center of Excellence
16 mai 2024 14h03 HE
|
Desert Hope Treatment Center
LAS VEGAS, May 16, 2024 (GLOBE NEWSWIRE) -- American Addiction Centers (AAC) has recognized Desert Hope Treatment Center as a Veterans Center of Excellence, highlighting its commitment to providing...
American Addiction Centers Names Oxford Treatment Center a Veterans Center of Excellence
16 mai 2024 12h24 HE
|
Oxford Treatment Center
OXFORD, Miss., May 16, 2024 (GLOBE NEWSWIRE) -- American Addiction Centers (AAC) has recognized Oxford Treatment Center as a Veterans Center of Excellence, highlighting its commitment to providing...
American Addiction Centers Names River Oaks Treatment Center a Veterans Center of Excellence
16 mai 2024 11h56 HE
|
River Oaks Treatment Center
RIVERVIEW, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- American Addiction Centers (AAC) has recognized River Oaks Treatment Center as a Veterans Center of Excellence, highlighting its commitment to...
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
07 mai 2024 07h46 HE
|
Clearmind Medicine Inc.
Vancouver, Canada, May 07, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
03 mai 2024 11h00 HE
|
PharmAla Biotech
PharmAla launches new educational resource for prescribers of MDMA through the Special Access Program
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
23 avr. 2024 08h15 HE
|
Silo Pharma, Inc.
Intranasal Delivery of SPC-15 shows rapid and effective drug exposure for PTSD Therapy SARASOTA, FL, April 23, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”),...
PharmAla Closes Private Placement and Concurrent Debt Settlement
19 avr. 2024 08h35 HE
|
PharmAla Biotech
PharmAla completes private placement and concurrent debt settlement with Advisor.
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
20 mars 2024 08h30 HE
|
Silo Pharma, Inc.
Exclusive license for development, manufacturing, and commercialization in process Silo Pharma to file Pre-IND in first half 2024 SARASOTA, FL, March 20, 2024 (GLOBE NEWSWIRE) -- Silo Pharma,...
Global Post-traumatic Stress Disorder (PTSD) Drug Pipeline Landscape Report 2024 Featuring Tonix Pharmaceuticals, Pop Test Oncology, H. Lundbeck, Bionomics, and Alto Neuroscience
29 févr. 2024 11h06 HE
|
Research and Markets
Dublin, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The "Post-traumatic Stress Disorder (PTSD) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report...
MAPS Congratulates Lykos Therapeutics on Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD
09 févr. 2024 19h30 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
The FDA has accepted Lykos Therapeutics' New Drug Application, supported by two decades of research incubated by MAPS, for MDMA-assisted therapy for PTSD.